



JFW

FILING RECEIPT

PLEASE DATE STAMP AND RETURN TO US - BOX 235X

In re application of

Akira TSUJI, et al.

Appln. No.: 10/541,019

Group Art Unit: 1615

Confirmation No.: 4031

Examiner: Unknown

Filed: June 28, 2005

For: GASTROINTESTINAL ABSORPTION ENHANCER MEDIATED BY PROTON-COUPLED
TRANSPORTER AND ITS PREPARING METHOD

PAPER(S) FILED ENTITLED:

1. Request for Corrected Official Filing Receipt
2. Marked up copy of Official Filing Receipt
3. Copy of Assignment filed June 28, 2005

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

DOCKET NO.: Q88424

ATTORNEY/SEC: GK/dmr

Date Filed: March 22, 2006

WASHINGTON OFFICE
23373

CUSTOMER NUMBER



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q88424

Akira TSUJI, et al.

Appln. No.: 10/541,019

Group Art Unit: 1615

Confirmation No.: 4031

Examiner: Unknown

Filed: June 28, 2005

For: GASTROINTESTINAL ABSORPTION ENHANCER MEDIATED BY PROTON-COUPLED TRANSPORTER
AND ITS PREPARING METHOD

REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

ATTN: Office of Initial Patent Examination
Filing Receipt Correction
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

We enclose a copy of the Official Filing Receipt for the above-identified application and request the following correction(s):

Assignment for Published Patent Application: Akira Tsuji and Otsuka Pharmaceutical Co. Ltd.

Title: ~~Agent improving proton-driven transporter-mediated absorption in digestive tract and process for producing the same;~~ Gastrointestinal Absorption Enhancer mediated by proton-coupled transporter and its preparing method.

Verification for the requested correction(s) is indicated on the Assignment filed June 28, 2005.

Respectfully submitted,


Gordon Kit
Registration No. 30,764

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: March 22, 2006



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/541,019	06/28/2005	✓ 1615	1300	Q88424 ✓	6	19	5

CONFIRMATION NO. 4031

23373
SUGHRUE MION, PLLC
2100 PENNSYLVANIA AVENUE, N.W.
SUITE 800
WASHINGTON, DC 20037

FILING RECEIPT



OC000000018061565

Date Mailed: 02/28/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Akira Tsuji, Kanazawa-shi, JAPAN; ✓
Ikumi Tamai, Kanazawa-shi, JAPAN; ✓
Yoshimichi Sai, Kanazawa-shi, JAPAN; ✓
Masaaki Odomi, Tokushima-shi, JAPAN; ✓
Hidekazu Toyobuku, Tokushima-shi, JAPAN; ✓

Assignment for Published Patent Application:

✓ Akira Tsuji and
Power of Attorney: The patent practitioners associated with Customer Number 23373.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/JP04/00070 01/08/2004 ✓

*Otsuka
Pharmaceutical
Co. Ltd.*

Foreign Applications

JAPAN 2003-6005 01/14/2003 ✓

Projected Publication Date: To Be Determined - pending completion of Security Review

Non-Publication Request: No

Early Publication Request: No

Title

Agent improving proton-driven transporter-mediated absorption in digestive tract and process for producing the same

Preliminary Class

514

Gastrointestinal Absorption enhancer mediated by
proton-coupled transporter and its preparing
method.

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.


The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

Assignment

Whereas, I/We, 1) TSUJI Akira, 2) TAMAI Ikumi, 3) SAI Yoshimichi, 4) ODOMI Masaaki, and 5) TOYOBUKU Hidekazu
See the Attached Sheet



hereinafter called assignor(s), have invented certain improvements in
GASTROINTESTINAL ABSORPTION ENHANCER MEDIATED BY PROTON-COUPLED TRANSPORTER
AND ITS PREPARING METHOD

and executed an application for Letters Patent of the United States of America therefor on
May 25, 2005; and

Whereas,

1) TSUJI Akira, and 2) OTSUKA PHARMACEUTICAL CO., LTD., of

1) 1-3-10, Nagamachi, Kanazawa-shi, Ishikawa 9200865, Japan; and

2) 9, Kandatsukasa-cho 2-chome, Chiyoda-ku,
Tokyo 1018535, Japan

(assignee), desires to acquire the entire right, title, and interest in the application and
invention, and to any United States patents to be obtained therefor;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,

I/We, the above named assignor(s), hereby sell, assign and transfer to the above named
assignee, its successors and assigns, the entire right, title and interest in the application and the
invention disclosed therein for the United States of America, including the right to claim priority
under 35 U.S.C. § 119, and I/we request the Director - U.S. Patent and Trademark Office to issue
any Letters Patent granted upon the invention set forth in the application to the assignee, its
successors and assigns; and I/we will execute without further consideration all papers deemed
necessary by the assignee in connection with the United States application when called upon to
do so by the assignee.

I/We hereby authorize and request our attorneys SUGHRUE MION, PLLC of 2100
Pennsylvania Avenue, NW, Washington, DC 20037-3213 to insert here in parentheses
(Application number _____ and Confirmation number _____

_____, filed _____) the filing date
and application number of said application when known.

Date: May 25, 2005

s/ TSUJI Akira

Date: May 25, 2005

s/ TAMAI Ikumi

Date: May 25, 2005

s/ SAI Yoshimichi

Date: May 25, 2005

s/ ODOMI Masaaki

Date: May 25, 2005

s/ TOYOBUKU Hidekazu

Date:

s/

Date:

s/

Date:

s/



-Attached Sheet-

The Assignors' Addresses

- 1) TSUJI Akira
1-3-10, Nagamachi, Kanazawa-shi, Ishikawa 9200865, Japan
- 2) TAMAI Ikumi
9-24, Midorigaoka, Kanazawa-shi, Ishikawa 9218117, Japan
- 3) SAI Yoshimichi
2-9-17-105, Izumigaoka, Kanazawa-shi, Ishikawa 9218035,
Japan
- 4) ODOMI Masaaki
c/o Formulation Research Institute of OTSUKA PHARMACEUTICAL
CO., LTD., 224-18, Hiraishi Ebisuno, Kawauchi-cho,
Tokushima-shi, Tokushima 7710182, Japan
- 5) TOYOBUKU Hidekazu
c/o Formulation Research Institute of OTSUKA PHARMACEUTICAL
CO., LTD., 224-18, Hiraishi Ebisuno, Kawauchi-cho,
Tokushima-shi, Tokushima 7710182, Japan